GPC3 and metabolic dysfunction-associated steatohepatitis: Recently, the NASH mouse model (named STAM mice C57BL/6N-NASH), which had a B6 background and spontaneously developed liver cancer, was exploited by Stelic Institute & Co. In this mouse model, the cancer incidence rate is high and cancer incident time is short, thus, STAM mice C57BL/6N-NASH is an attractive model for studying GPC3-targeted therapy for HCC.